businessbriefs
10:50in productionCh. 1 · Born from separation/ 10:50 · ceiling 15 min
Companies

AbbVie

2012

AbbVie didn’t win the autoimmune market with science — it won with patents, pricing, and settlements.

AbbVie is a textbook example of post-innovation pharmaceutical value extraction — built on a single blockbuster, sustained by patent thickets and pricing, checked only by biosimilars and congressional scrutiny.

CompaniesPatentsMonopolyPhotographyPatents across the network →
Chapters & takeaways5
  1. 1:21
    Born from separation

    AbbVie exists because Abbott Laboratories spun it off in 2012 — not to launch something new, but to isolate high-margin drugs from slower-growth businesses.

  2. 3:05
    The Humira decade

    Humira dominated for a decade by treating six autoimmune diseases — then lost exclusivity when biosimilars entered in January 2023.

  3. 4:14
    Patent as barrier

    A congressional committee found AbbVie exploited the patent system to extend its monopoly — not an allegation, but a documented finding.

  4. 5:25
    Price of promotion

    AbbVie paid $24 million in 2020 to resolve kickback allegations — proof its commercial tactics crossed legal lines.

  5. 7:06
    The Kaletra misfire

    Its attempt to repurpose Kaletra for COVID-19 failed in the first non-blinded, randomized trial — exposing limits of opportunistic development.

Worth your time?

Yes. Study the whole thing.

4/ 5
What works
  • monetising a single molecule across multiple indications
  • extending exclusivity through sequential patents
  • leveraging scale to settle litigation rather than litigate
What does not
  • innovate clinically beyond Humira’s original indication
  • maintain pricing power after biosimilar entry
  • avoid regulatory penalties for commercial conduct
Study it if
  • healthcare investors
  • policy analysts
  • pharma strategists
Skip it if
  • biotech founders seeking R&D inspiration
  • patients evaluating treatment options
The written brief1 min read

What the company or idea is

AbbVie is an American pharmaceutical company formed in 2012 via spin-off from Abbott Laboratories and listed publicly in January 2013.

How it actually makes money

AbbVie makes money primarily from Humira, an injectable autoimmune drug that generated $9 billion in 2024 — 16% of its total revenue.

What works

Humira treats six autoimmune conditions — rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, Crohn’s disease and ulcerative colitis — and retained market dominance until biosimilar competition began in January 2023.

What does not

Kaletra/Aluvia was not useful to treat severe COVID-19, per a non-blinded, randomized trial.

What to take from it

A company can dominate a therapeutic category for over a decade not by inventing new mechanisms, but by extending monopoly through patents, pricing, and legal settlements — while facing real consequences only when Congress or courts intervene.

Is it worth your time

Yes — as a case study in how patent strategy, regulatory capture, and pricing power shape pharmaceutical profits long after clinical innovation ends.

Same desk · Companies4 of 217
12:57
MeituanWang Xing · 2010Meituan is a Chinese technology company headquartered in Beijing that operates a platform for local services, including on‑demand food delivery, in‑store services, consumer reviews under Dazhong Dianping, hotel and travel bookings, and instant retail. It monetises through fees on its platform, taking a commission on food delivery orders and charging merchants for booking and in‑store services. Meituan’s rapid user growth is driven by its extensive coverage of local services, its integration of food delivery, in‑store services, and hotel bookings creating a one‑stop shop, and its large merchant base of 14.5 million active merchants providing network effects. Meituan faces regulatory scrutiny in China, its 2021 post by Wang Xing triggered a 7.1 % share plunge and anti‑monopoly investigation, and the company has been subject to scrutiny by Beijing Municipal Human Resources and Social Security Bureau. Meituan demonstrates the power of a diversified local‑services platform, its ability to scale across cities and internationally shows the importance of network effects, and its regulatory challenges highlight the need for compliance awareness. Meituan offers a case study in rapid scaling and diversification, but its regulatory risks caution investors.
10:56
ABBCharles Eugene Lancelot Brown · 1988ABB is a post-merger industrial incumbent whose value lies in proven, regulated, physical infrastructure — not software, platforms, or scalability stories.
11:08
Abu Dhabi National Oil Company1971ADNOC is the state-owned oil company of Abu Dhabi, UAE — founded by concession in 1939, ranked 12th globally by production, and expanding output to 5 million barrels per day by 2027. It is the UAE’s largest oil company. Output rose from ~2.5 mbpd in the 1990s to 2.9 mbpd in 2008 and 4.85 mbpd in 2024. It is described as efficient and well managed, but financially opaque. It is one of few oil companies increasing production amid climate pressure.
10:55
Air Canada1937Air Canada is Canada’s state-founded, privatised, hub-based flag carrier—large by fleet and passengers, anchored in Montreal, Toronto, and Vancouver, and embedded in Star Alliance. It carried 45.3 million passengers in 2025. It was founded in 1937 as Trans-Canada Air Lines, renamed in 1965, privatised in 1988, acquired Canadian Airlines in 2000, and filed for bankruptcy protection in 2003 before emerging in 2004.
Up next in Business

Abu Dhabi National Oil Company

1971 · 11:08

ADNOC is expanding oil production while the rest of the industry retreats — not because it ignores climate change, but because it answers to no one but Abu Dhabi.

Play nextBack to Companies
11:08